Cellectis S.A. (CLLS) vs Foghorn Therapeutics (FHTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Foghorn Therapeutics (FHTX) has outperformed Cellectis S.A. (CLLS) over the past year, losing 55.8% versus a loss of 70.9%. Over five years, FHTX leads with a -83.9% price change compared with -88.5% for CLLS. Cellectis S.A. is the larger company by market cap ($125.9 million vs $118.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | FHTX |
|---|---|---|
| Share price | $1.25 | $1.99 |
| Market cap | $125.90M | $118.18M |
| 1-day change | -6.72% | -4.78% |
| YTD return | -74.17% | -63.15% |
| 1-year return | -70.93% | -55.78% |
| 5-year return | -88.46% | -83.93% |
| EPS (TTM) | $-0.64 | $-0.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.48 | $7.61 |
| 52-week low | $1.22 | $1.79 |
| Distance from 52-week high | -77.19% | -73.85% |
| Analyst consensus | none | buy |
| Avg. price target upside | +326.40% | +201.51% |
| Average volume | 80.14K | 629.61K |
| Shares outstanding | 72.72M | 59.39M |
| Employees | 224 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FHTX has outperformed CLLS by 15.2 percentage points over the past year.
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
CLLS vs FHTX FAQ
Which is bigger, Cellectis S.A. or Foghorn Therapeutics?
Cellectis S.A. (CLLS) is larger, with a market capitalization of $125.90M compared with $118.18M for Foghorn Therapeutics (FHTX).
Which stock has performed better over the past year, CLLS or FHTX?
FHTX returned -55.78% over the past 12 months, compared with -70.93% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and Foghorn Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.